Searched for
PHARMATHEN
Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...- Cipla shares slide 5% after temporary halt in key drug manufacturingCipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply ...
- High valuations not a deterrent for India deals: Partners' CEO"Private market investors have to pay aggressive multiples to access India's growth potential. Yes, it's a high price, but per unit of grow...
- How a chaotic Grexit could wipe out $1.4 trillion in future mergers and acquisitionsTransactions in the US and China may also be affected, resulting in lost deals worth about $700 billion in the two countries through 2020.
- Panacea Biotec plans to foray European marketThe company’s Baddi plant has received the German drug regulator’s approval and expects to get approval of three of its drugs by September ...
- Panacea to buy 19.9% in PharmAthene for $13.1 mnVaccine maker Panacea Biotec has agreed to buy 19.9% in US-based PharmAthene for $13.1 mn.
- Panacea enters into alliance with US-based PharmAtheneVaccine manufacturer Panacea Biotec on Wednesday said it has entered into a strategic alliance with US-based PharmAthene and will invest 13...
Load More